Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis

详细信息    查看全文

• 作者：Scott Martin Vouri^a ; ^{scott.vouri@stlcop.edu} ; Clark D. Kebodeaux^b ; Paul M. Stranges^c ; Besu F. Teshome^a
• 关键词：AE ; adverse event ; OAB ; overactive bladder ; ER ; extended ; release ; IR ; immediate release ; NNH ; number needed to harm ; PRIMSA ; Preferred Reporting Items for Systematic Reviews and Meta-Analysis ; RCT ; randomized controlled trial ; SRMA ; systematic review and meta-analysis
• 刊名：Archives of Gerontology and Geriatrics
• 出版年：2017
• 出版时间：March-April 2017
• 年：2017
• 卷：69
• 期：Complete
• 页码：77-96
• 全文大小：650 K
• 卷排序：69

文摘

There are higher rates of anticholinergic AEs like dry mouth and constipation and treatment discontinuation in antimuscarinics versus placebo in the elderly. There are higher rates of non-anticholinergic AEs, such as dyspepsia, dizziness, headache, and urinary tract infections in antimuscarinics versus placebo in the elderly. In head-to-head trials, there are higher rates of AEs in fesoterodine compared to tolterodine extended-release in the elderly. Due to the restrictive inclusion and exclusion criteria, these results should be further confirmed using pharmacoepidemiological techniques.